Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection.
Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection.
复制标题
DOI：
10.1016/j.omto.2023.08.014
复制
发表时间：
2023-09-21
期刊：
影响因子：
--
通讯作者：
Bartee, Eric
中科院分区：
文献类型：
--
作者：
Thomas, Raquela J.;Bartee, Mee Y.;Valenzuela-Cardenas, Miriam;Bartee, Eric
溶瘤病毒作为治疗癌症的新方法正在被大量研究;然而，预测其治疗效果仍然具有挑战性。最常用的预测性试验包括测定肿瘤恶性细胞对溶瘤剂感染的体外敏感性。然而，这些测试是否真正预测体内疗效仍不清楚。在这里，我们证明了重组的溶瘤粘液瘤病毒在两种三阴性乳腺癌小鼠模型中显示出有效性，尽管这些模型对病毒感染的风险极低。这些数据表明，体外感染性研究不是治疗效果的准确替代品，并表明需要开发其他测试。Bartee及其同事表明，重组溶瘤粘液瘤病毒在两种三阴性乳腺癌小鼠模型中显示出疗效，尽管这些模型对病毒感染的风险极低。
Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the in vitro susceptibility of a tumor’s malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of in vivo efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that in vitro infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed. Bartee and colleagues show that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection.
登录
查看更多内容
影响因子：
9.2
作者：
通讯作者：
--
影响因子：
4.7
作者：
通讯作者：
--
影响因子：
2.6
作者：
Yarde, Danielle N.;Nace, Rebecca A.;Russell, Stephen J.
通讯作者：
Russell, Stephen J.
影响因子：
5.4
作者：
Wolfe, A. M.;Dunlap, K. M.;Bartee, E.
通讯作者：
Bartee, E.
影响因子：
24.8
作者：
Dai P;Wang W;Yang N;Serna-Tamayo C;Ricca JM;Zamarin D;Shuman S;Merghoub T;Wolchok JD;Deng L
通讯作者：
Deng L